Recently, the Prescription Medicines Code of Practice Authority announced in a press release that 5 pharmaceutical companies have breached the Association of the British Pharmaceutical Industry’s Code of Practice.
Recently, the Prescription Medicines Code of Practice Authority (PMCPA) announced in a press release that 5 pharmaceutical companies have breached the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice. The code reflects and extends beyond UK law, and is administered by the PMCPA as part of a self-regulatory system that covers prescription medicines.
PMCPA publicly reprimanded Sunovion Pharmaceuticals Europe LTD for allowing 1 of its managers to encourage staff to suggest to customers that they could face legal action if they did not consider lurasidone (Latuda) as part of a patient review. It was ruled that Sunovion was in breach for failing to maintain a high standard of ethical conduct in the field, and for providing verbal direction that advocated a course of action that would lead to a breach of the Code. The public reprimand appears on the front cover of the PMCPA November 2017 Code of Practice Review. Subsequently, the Code of Practice Appeal Board also required Sunovion to be audited.
Additionally, all of the following companies were cited for, among other issues, bringing discredit to and reducing confidence in the pharmaceutical industry:
The full case reports are published in the PMCPA November 2017 Code of Practice Review, and are also available at www.pmcpa.org.uk.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.